Procalcitonin: changes and outcomes in pediatric  sepsis at Chiang Mai University Hospital

Sunkonkit K; Chanyutthana S; Reungrongrat S

Authors

Sunkonkit K Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Thailand
Chanyutthana S Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Thailand
Reungrongrat S Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Thailand

Keywords:

procalcitonin, sepsis, children, intensive care

Abstract

Objectives Among a large array of laboratory tests for identifying sepsis, procalcitonin (PCT) has emerged as the leading biomarker for indicating sepsis accurately and in a timely manner. Our study aimed to characterize the change in PCT levels in pediatric sepsis cases and to determine the association with mortality, length of stay (LOS) in the pediatric ICU, and PRISM III score.

Methods In this prospective observational study, pediatric patients diagnosed with sepsis and septic shock were enrolled. Demographic information, laboratory data and PCT levels at 0-24 hours and at 72-96 hours after admission were collected. PRISM III scores were assessed and 28-day mortality and LOS were recorded.

Results Sepsis severity in the 58 children enrolled (median age 14.5 months, range 1-180 months) was classified as both sepsis (n=19, 32.7%) and septic shock (n=39, 67.2%). Respiratory tract infection was the most common cause. We found that a PCT level of 1.38 ng/mL can be used to distinguish between sepsis and septic shock with a sensitivity of 76.9% and a specificity of 68.4%. A reduction in PCT of less than 15% following treatment was associated with a higher mortality rate (OR 70.4, 95% CI, 7.23-685.08; p <0.001), but was not associated with LOS in the pediatric intensive care unit (PICU) or PRISM III score.

Conclusion PCT level can be used to classify sepsis severity. A reduction in PCT level of 15% or more within 72-96 hours after treatment is associated with an improved survival rate, but is not associated with LOS in PICU or with PRISM III score.

References

1. Carcillo JA. Reducing the global burden of sepsis in infants and children: A clinical practice research agenda. Pediatr Crit Care Med. 2005; 6:S157-64.
2. Hartman ME, Linde-Zwirble WT, Angus DC, Watson RS. Trends in the epidemiology of pediatric severe sepsis. Pediatr Crit Care Med. 2013; 14:686-93.
3. Henriquez-Camacho C, Losa J. Biomarkers for sepsis. Biomed Res Int. 2014; 2014:547818.
4. Chaudhury A, Sachin Sumant GL, Jayaprada R, Kalawat U, Ramana BV. Procalcitonin in sepsis and bacterial
infections. J Clin Sci Res. 2013; 2:216-24.
5. Pavoa P, Salluh JI. Biomarker guided antibiotic therapy in adult critically ill patients: a critical review. Ann
Intensive Care. 2012; 2: 32.
6. Lanziotti VS, Póvoa P, Soares M, Silva JRL, Barbosa AP, Figueira JI. Use of biomarkers in pediatric sepsis: literature review. Rev Bras Ter Intensiva. 2016;28:472-82.
7. Standage SW, Wong HR. Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther. 2011;9:71-9.
8. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36:941-52.
9. Samsudin I, Vasikaran SD. Clinical utility and measurement of procalcitonin. Clin Biochem Rev. 2017;38:59-86.
10. Chiesa C, Panero A, Rossi N, Stegagno M, De Giusti M, Osborn JF, et al. Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. Clin Infect Dis. 1998; 26:664-72.
11. Shiferaw B, Bekele E, Kumar K, Boutin A, Frieri M. The role of procalcitonin as a biomarker in sepsis. J Infect Dis Epidemiol. 2016;2:1-4.
12. Achra A, Narsaria P, Lodha R, Kabra SK, Kapil A. Procalcitonin in pediatric intensive care unit of a
tertiary care hospital. J Epidemiol Global Health. 2016; 4:80-2.
13. Fioretto JR, Martin JG, Kurokawa CS, Carpi MF, Bonatto RC, de Moraes MA, et al. Comparison between procalcitonin and C-reactive protein for early diagnosis of children with sepsis and septic shock. Inflamm Res. 2010; 59:581-6.
14. Arkader R, Troster EJ, Lopes MR, Júnior RR, Carcillo JA, Leone C, et al. Procalcitonin does discriminate
between sepsis and systemic inflammatory response syndrome. Arch Dis Child. 2006; 91:117-20.
15. Han YY, Doughty LA, Kofos D, Sasser H, Carcillo JA. Procalcitonin is persistently increased among children with poor outcome from bacterial sepsis. Pediatr Crit Care Med. 2003; 4:21-5.
16. Casado-Flores J, Blanco-Quirós A, Asensio J, Arranz E, Garrote JA, Nieto M. Serum procalcitonin in children with suspected sepsis: A comparison with C-reactive protein and neutrophil count. Pediatr Crit Care Med. 2003; 4:190-5.
17. Hatherill M, Tibby SM, Turner C, Ratnavel N, Murdoch IA. Procalcitonin and cytokine levels: relationship to organ failure and mortality in pediatric septic shock. Crit Care Med. 2000; 28:2591-4.
18. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580-637.
19. Pollack MM, Ruttimann UE, Getson PR. Pediatric risk of mortality (PRISM) score. Crit Care Med. 1988;16: 1110-6.
20. Müller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-1 gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86:396-404.
21. Garcia IJ, GargalloMB, Torné EE, Lasaosa FJ, Viñas AT, Tolosa CV, et al. Procalcitonin: a useful biomarker to discriminate infection after cardiopulmonary bypass in children. Pediatr Crit Care Med. 2012; 13:441–5.
22. Pierce R, Bigham M, Giuliano Jr JS. Use of procalcitonin for the prediction and treatment of acute bacterial infection in children. Curr Opin Pediatr. 2014;26:292-8.
23. Yo CH, Hsieh PS, Lee SH, Wu JY, Chang SS, Tasi KC, et al. Comparison of the test characteristics of procalcitonin to C-reactive protein and leukocytosis for the detection of serious bacterial infections in children presenting with fever without source. A systematic review and meta-analysis. Ann Emerg Med. 2012;60:591-600.
24. England JT, Del Vecchio MT, Aronoff SC. Use of serum procalcitonin in evaluation of febrile infants: a meta-analysis of 2317 patients. J Emerg Med. 2014; 47:682-8.
25. Rey C, Los Arcos M, Concha A, Medina A, Prieto S, Martinez P, et al. Procalcitonin and C-reactive protein as markers of systemic inflammatory response syndrome severity in critically ill children. Intensive Care Med. 2007; 33:477-84.
26. Zurek J, Vavrina M. Procalcitonin biomarker kinetics to predict multiorgan dysfunction syndrome in children with sepsis and systemic inflammatory response syndrome. Iran J Pediatr. 2015; 25: e324.
27. Poddar B, Gurjar M, Singh S, Aggarwal A, Baronia A. Reduction in procalcitonin level and outcome in critically ill children with severe sepsis/septic shock-A pilot study. J Crit Care. 2016;36:230-3.
28. Huang MY, Chen CY, Chien JH, Wu KH, Chang YJ, Wu KH, et al. Serum procalcitonin and procalcitonin clearance as a prognostic biomarker in patients with severe sepsis and septic shock. Biomed Res Int. 2016; 2016:1758501.
29. Pieralli F, Vannucchi V, Mancini A, Antonielli E, Luise F, Sammicheli L, et al. Procalcitonin kinetics in the first 72 hours predicts 30 day mortality in severely ill septic patients admitted to an Intermediate Care Unit. J Clin Med Res. 2015; 7:706-13